Tenon Medical, Inc. · NASDAQ:TNON
Tenon Medical — Investor Presentation (May 2022)
21 slides from Tenon Medical's investor presentation, May 31, 2022
Slide 1: Investor Presentation June 2022
Investor Presentation June 2022
Slide 2: Safe Harbor
2 Safe Harbor This presentation contains “forward - looking statements,” which are statements related to events, results, activities or developments that Tenon Medical expects, believes or anticipates will or may occur in the future . Forward - looking often contain words such as “intends,” “estimat
Slide 3: Key Highlights
• Transformative implant system addressing significant unmet market opportunity • Large / growing underserved market • Designed to produce broad and demonstrable advantages over market competitors: • Known Approach – Away from Neural and Vascular Structures • Optimally Designed Implant • Better Outc
Slide 4: What Are We Treating?
4 What Are We Treating? 25% + Of All Low Back Pain (LBP) Sacroiliac (SI) Joint • Last segment of the spine • Connects Sacrum to Ilium Pain That Disrupts Quality of Life
Slide 5: A Major Untapped Market Opportunity
Global Sacroiliac (SI) Joint Fusion market is estimated to grow to $661M by 2028 . SOURCE: Grand View Research, Inc. • 18% + CAGR Driven By: • Improved Surgical Approaches • Specialized Implant Design • Procedure Safety and Efficiency • Enhanced Physician Reimbursement • Physician Recognition Growin
Slide 6: A Better Option for SI Joint Fusion
6 A Better Option for SI Joint Fusion • Optimized surgical approach for SI Joint Fusion • A specifically designed titanium implant & delivery tools for surgery through a mini - open posterior/inferior approach • Bridges the sacrum & the ilium to stabilize the joint • Implant filled with autologous b
Slide 7: Optimized Surgical Approach
7 Optimized Surgical Approach SI - Bone / Other Lateral Catamaran™ Significant Tissue Disruption Substantial Post - Op Pain No Direct Visualization Trajectory Towards Neural and Vascular Structures Minimal Tissue Disruption Minor Post - Op Pain Known Approach (same as injection) with Visualization T
Slide 8: Optimized Implant Design
8 Optimized Implant Design SI - Bone / Other Lateral Catamaran™ Triangular Rods, Cages or Screws limited in function No use of Bone Graft Material critical for Fusion Multiple devices required to fixate the joint No joint preparation known to promote fusion Specifically designed implant to span the
Slide 9: Patient Outcomes – The Catamaran System
9 Patient Outcomes – The Catamaran™ System Tenon CATAMARAN ® Published Results 58 - 74% 88% 1) Initial study with N=18 2) Schmidt GL, Bologna M, Schorr R.Orthop Surg. 2020 Dec 7. [ Epub ahead of print]. Significant and Sustained Reduction in SIJ Pain (VAS) 1,2 Early clinical experience has shown Cat
Slide 10: Established Reimbursement & Coding Flexibility
10 Established Reimbursement & Coding Flexibility 58 - 74% 88% SI Joint Arthrodesis Coding Summary Existing ICD - 10 Codes (Facilities) Existing CPT Codes (Provider) Medicare averages as reported. Non - Medicare payers have their own methodology for paying providers. Licensed Coders and Reimbursemen
Slide 11: Compelling Benefits to all Stakeholders
11 Compelling Benefits to all Stakeholders Physicians Hospitals Payor Patients • An established procedure with an increased revenue stream through facility payments • Access a large pool of new patients who do not qualify for minimally invasive SIJ reimbursement • Competitive differentiation • More
Slide 12: Strong IP Position
12 Strong IP Position Six issued and eight pending patents for a broad range of claims including a posterior / inferior approach to Sacroiliac Joint Fusion Claims directed to systems and methods Additional patents pending OUS Developing new cases to expand claims
Slide 13: Our Go to Market Strategy
13 Our Go to Market Strategy Targeting • High Adoption SI Fusion Markets / Accounts • Physicians Previously Trained on SI • Build Referral Bridge Between Pain and Surgery Physicians • Established Physician Faculty • Established regional training centers (logistical optimization) • Virtual • Model Ba
Slide 14: Our Go to Market Strategy – Expansion Steps
14 Our Go to Market Strategy Training Initial Commercialization Step 2 Expansion Step 3 Expansion Step 4 Expansion P1 High Adoption Markets - Training Phase 1 Support and Advocacy P2 High Adoption Markets - Training
Slide 15: National Distribution
15 National Distribution 58 - 74% 88% Tom Mitchell President and CEO SpineSource is Tenon’s Exclusive National Distributor with 30+ years of orthopedic sales experience and 700+ independent sales personnel spanning the US • Commission based agreement (not a stocking distributor) • Tenon Medical Qual
Slide 16: SpineSource Partnership Competitive Advantage
16 SpineSource Partnership Competitive Advantage 58 - 74% 88% Tom Mitchell President and CEO • Immediate Nationwide Access to Skilled and Knowledgeable Distributors • Cost Effective Approach vs. Tenon Hiring Internal Personnel To Handle Many Functions • Competitors Spending 90%+ on Sales and Marketi
Slide 17: Tenon Medical – 2021 and Early 2022
17 Tenon Medical – 2021 and Early 2022 58 - 74% 88% Tenon 2021 Accomplishments • Physician Advisors Identified • Finalized Instrumentation and Technique Refinement • Secured Supply Chain to Meet 2022 Demand • Hired Key Personnel to support 2022 Plan • Refined Physician Training Program • National Di
Slide 18: Experienced Management Team
18 Experienced Management Team 58 - 74% 88% Track Record of Building Successful MedTech Companies Richard Ferrari, Founder, Executive Chairman Steven Foster President and CEO Steve Van Dick Executive VP and CFO Richard Ginn Founder, CTO
Slide 19: Investment Rationale
19 Investment Rational FDA Cleared, Reimbursement Secured, Commercial Stage • Near Term Revenue – Launching Q1, 2022 • SI Joint Market Growing at 18% CAGR • Clear Opportunity and Need for a Better Way • Optimized Approach • Optimized Implant • Authentic and Demonstrable Fusion • Procedure Efficiency
Slide 20: Key Takeaways
20 Key Takeaways Catamaran™ SI Fusion System Delivers: • Radiographic Confirmation of Fusion • Fixation with enhanced surface area spanning the joint A Picture is Worth a Thousand Words
Slide 21: Contact Us
21 Contact Us 58 - 74% 88% Tenon Medical, Inc. 104 Cooper Court Los Gatos, CA 95032 (408) 649 - 5760 www.tenonmed.com Investor Relations Contact: Shannon Devine Managing Director 203 - 741 - 8811 Tenon@mzgroup.us